The Beta-1-Receptor Blocker Nebivolol Elicits Dilation of Cerebral Arteries by Reducing Smooth Muscle [Ca2+]i by Cséplő, Péter et al.
RESEARCH ARTICLE
The Beta-1-Receptor Blocker Nebivolol Elicits
Dilation of Cerebral Arteries by Reducing
SmoothMuscle [Ca2+]i
Peter Cseplo1,2, Zoltan Vamos1,3, Ivan Ivic1,4, Orsolya Torok1, Attila Toth5,
Akos Koller1,6,7,8*
1 Institute for Translational Medicine and Szentagothai Research Centre, University of Pecs, Medical
School, Pecs, Hungary, 2 Department of Central Anesthesiology and Intensive Therapy, Petz Aladar County
Teaching Hospital, Gyor, Hungary, 3 Department of Anaesthesiology and Intensive Therapy, University of
Pecs, Medical School, Pecs, Hungary, 4 Department of Anatomy, University of Pecs, Medical School, Pecs,
Hungary, 5 Institute of Cardiology, Division of Clinical Physiology, Faculty of Medicine, University of
Debrecen, Debrecen, Hungary, 6 Department of Neurosurgery, University of Pecs, Medical School, Pecs,
Hungary, 7 Department of Physiology, New York Medical College, Valhalla, New York, United States of
America, 8 Institute of Natural Sciences, University of Physical Education, Budapest, Hungary
* koller.akos@tf.hu
Abstract
Rationale
Nebivolol is known to have beta-1 blocker activity, but it was also suggested that it elicits
relaxation of the peripheral arteries in part via release of nitric oxide (NO). However, the
effect of nebivolol on the vasomotor tone of cerebral arteries is still unclear.
Objective
To assess the effects of nebivolol on the diameter of isolated rat basilar arteries (BA) in
control, in the presence of inhibitors of vasomotor signaling pathways of know action and
hemolysed blood.
Methods and Results
Vasomotor responses were measured by videomicroscopy and the intracellular Ca2+ by
the Fura-2 AM ratiometric method. Under control conditions, nebivolol elicited a substantial
dilation of the BA (from 216±22 to 394±20 μm; p<0.05) in a concentration-dependent man-
ner (10−7 to 10−4 M). The dilatation was significantly reduced by endothelium denudation or
by L-NAME (inhibitor of NO synthase) or by SQ22536 (adenylyl cyclase blocker). Dilatation
of BA was also affected by beta-2 receptor blockade with butoxamine, but not by the guany-
late cyclase blocker ODQ. Interestingly, beta-1 blockade by atenolol inhibited nebivolol-
induced dilation. Also, the BKCa channel blocker iberiotoxin and KCa channel inhibitor TEA
significantly reduced nebivolol-induced dilation. Nebivolol significantly reduced smooth
muscle Ca2+ level, which correlated with the increases in diameters and moreover it
reversed the hemolysed blood-induced constriction of BA.
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Conclusions
Nebivolol seems to have an important dilator effect in cerebral arteries, which is mediated
via several vasomotor mechanisms, converging on the reduction of smooth muscle Ca2+
levels. As such, nebivolol may be effective to improve cerebral circulation in various dis-
eased conditions, such as hemorrhage.
Introduction
Many cerebral diseases (hypertensive encephalopathy, vascular cognitive impairment, Alzhei-
mer’s disease, traumatic brain injury or stroke) are associated with impaired regulation of cere-
bral blood flow. [1]. Thus experimental and clinical investigations aim to improve regulation of
cerebral blood flow by pharmacologicalmeans [2]. In addition to the improvement of the mod-
ulatory role of endothelium (for example via nitric oxide (NO) [3–6], the restoration of the
appropriate regulation of smoothmuscle tone of cerebral vessels is also of great importance.
One of the most frequently used therapeutic agents modulating the regulation of cardiovas-
cular system are the so called beta blockers, among others is Nebivolol a 3rd generation beta-1
blocker [7, 8]. It is a mixture of the 2 enantiomers, D-nebivolol (+SRRR) and L-nebivolol
(-RSSS) [9] [8, 10]. Nebivolol possesses vasodilator properties [8, 11, 12]. Although, the pri-
mary indication of nebivolol in the treatment of hypertension [13], coronary artery disease
[14], heart failure [15] and atrial fibrillation [16] is due to its beta-1 receptor mediated action,
previous work by Ignarro et al [17] found that nebivolol elicits relaxation of canine coronary
and pulmonary artery by stimulating endothelial NO synthesis. Supporting this conclusion,
Gao et al [18] showed that nebivolol elicits endothelium-dependent relaxation in canine coro-
nary rings, whereas further studies also showed its dilator effects on human forearm veins and
arteries [19] [20].
As of today, there are no data regarding the direct effect of nebivolol on cerebral arteries
without the potential brain tissues-derived confounding factors. Thus in this study we aimed to
investigate the effects of nebivolol on the diameters of isolated basilar arteries isolated from rat
brain, in control condition and in the presence of inhibitors of vasomotor mechanisms of
knowmechanisms of action in a condition, when intraluminal pressure and the environment
were kept constant. During traumatic brain injury or cerebral hemorrhage the cerebral vessels
are exposed to hemolysed blood, a disease condition, which prevalence is increasing substan-
tially in world-wide [21, 22]. Previously, we have shown the extravascular hemolysed blood
elicits significant constrictions of basilar arteries. Thus we also aimed to test the hypothesis that
nebivolol can reverse the hemolysed blood-inducedconstriction of cerebral arteries [23]. The
importance of the study is justifiedwith the still limited availability of therapeutic means—
without major side effects—to improve cerebral blood flow supply in diseased conditions.
Materials and Methods
Animals
For these experiments ~2 months-old (250±50 g) maleWistar rats (Crl:WI, Charles River Ltd.,
Hungary; n = 5 to 10 in each group) were used. Animals were housed on a 12h light/dark cycle
and were fed ad-libitum on standard rat chow and free access to tap water. All experiments and
interventions were undertaken according to the general rules and special approval of the Uni-
versity of Pecs Ethical Committee for the Protection of Animals in Research (BA 02/2000-8/
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2008), in accordance with the directives of the National Ethical Council for Animal Research
and those of the EU Directive (2010/63/EU), in accordance with the ARRIVE guidelines.
Isolation of basilar arteries (BA) and measurements of their diameter
Cerebral vessels were isolated as we previously described [23–25]. In brief, animals were anes-
thetized by ether narcosis and decapitated according to Institutional Animal Care and Use
Committee of University of Pecs, Medical School, Pecs, Hungary. The brains were immediately
removed and placed in 4°C cold Krebs’ buffer. Basilar arteries (BA) were isolated from the
brain of each animal. Segments of the BAs were isolated using microsurgery instruments. Both
ends of the BAs were mounted onto two glass micropipettes in a vessel chamber and pressur-
ized to 80 mmHg with zero flow. The hydrodynamic resistances of the micropipettes were
matched. Inflow and outflow pressures were controlled and measured by a pressure servo-con-
trol system (Living Systems Instrumentation, Burlington, VT, USA). Inner vascular diameter
was measured with a video-micrometer system and continuously recorded using a computer-
ized data acquisition system (LabChart 7 pro by PowerLab, ADInstruments, Australia). All ves-
sels were allowed to stabilize for 60 min in oxygenated (21% O2; 5% CO2; 74% N2) superfused
Krebs’ buffer (at 37°C). After the equilibration period, during which spontaneous myogenic
tone developed (measured as basal diameter; BD), and the vascular responses were assessed, as
reported previously [23, 26–28]. At the end of each experiment, the passive diameters (PD)
of the vessels were measured at constant, 80 mmHg intraluminal pressure in the presence of
Ca2+-free Krebs’ buffer containing the L-type Ca2+ channel antagonist nifedipine (10−4 M) to
achieve maximal vasodilation.
Assessment of endothelial function
To evaluate the role of endothelium in the development of nebivolol induced dilation, the vas-
cular endotheliumwas removed, as describedpreviously [29]. The function of arteriolar endo-
thelium and smooth muscle was assessed before and after endothelium denudation. Arteriolar
dilations to a test dose of endothelium-dependent acetylcholine (ACh; 10−4 M) and endothe-
lium independent sodiumnitroprusside (SNP; 10−4 M) were obtained (n = 10). The endothe-
lium was denuded by perfusing the vessel with 2 ml air (2 x [1 ml air in 5 minutes]), then filled
and reperfusedwith Krebs’ buffer thus cleaning debris. Vessels achieved a steady-state diame-
ter in ~15 minutes, whereupon responses to ACh and SNP were retested (Fig 1(A) and 1(B)).
Administration of vasoactive agents and inhibitors
In the first series of experiments vasomotor function of vessels was studied in response to
increased concentrations (10−7 M to 10−4 M; n = 9) of nebivolol (Berlin-Chemie/A.Menarini
kft). To assess endothelial function, vascular responses to cumulative concentrations of acetyl-
choline (Ach; 10−4 M) were obtained. The intact vasomotor function of smooth muscle was
verified by dilation to sodium nitroprusside (SNP; 10−4 M).
In separate experimental series to assess the role of nitric oxide, endothelium-mediated
responses were reassessed in the presence of NO synthase inhibitor Nω-nitro-L-arginine
methyl ester (L-NAME [30]; 10−4 M; 20 min; Koller et al, 2004; n = 5). In other experiments
soluble guanylate cyclase was blocked by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ
[31]; 10−5 M, 30 min, n = 12). To assess the efficacy of ODQ, acetylcholine- and SNP-induced
(10−4 M) responses were obtained before and after incubation of vessels with ODQ. In other
experimental series adenylyl cyclase was blocked by 9- (tetrahydro- 2- furanyl)- 9H- purin- 6-
amine (SQ22536 [32, 33]; 10−4 M, 20 min, n = 9). In separate series of experiments to assess
the role of beta-1 adrenoceptors in the development of nebivolol-induced dilation, we have
Nebivolol Dilates Rat Cerebral Arteries
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Fig 1. Changes in basal diameter of basilar artery (BA) in response to endothelium denudation (Fig 1(A);
n = 10; E+ endothelium intact; E- endothelium denuded), NO synthase inhibitor L-NAME (Fig 1(C); n = 5),
adenylyl cyclase inhibitor SQ22536 (Fig 1(D); n = 9), guanylate cyclase inhibitor ODQ (Fig 1(E); n = 12) and
increasing concentration (10−6 to 10−4 M) of beta-1 adrenoceptor blocker atenolol (Fig 1(G); n = 10). To assess
the vascular function acetylcholine (Ach) and sodium nitroprusside (SNP) test-doses were applied before and
after the endothelial denudation (Fig 1(B); n = 10; E+ endothelium intact; E- endothelium denuded). Summary
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used beta-1 adrenoceptor antagonist atenolol (10−6 to 10−4 M; n = 8). In other experiments to
investigate the role of beta-2 specific adrenoceptors in the development of nebivolol-induced
dilation, beta-2 specific adrenoceptor antagonist butoxamine [34, 35] was used (BTXN; 10−4
M, 15 min, n = 5). To assess the function of Ca2+-activated potassium channels in the develop-
ment of nebivolol-induced dilation, Ca2+-activated potassium channel were blocked by tetra-
ethylammonium [34, 35] (TEA; 10−3 M, 15 min; n = 10) or large conductance Ca2+-activated
potassium channels were blocked by iberiotoxin [34, 35] (IBTX; 10−7 M, 15 min; n = 5). Other
experimental series tested the effect of nebivolol on BA in the presence of endothelium denuda-
tion (n = 10) or specific blockers separately LNAME (n = 5), ODQ (n = 8), SQ (n = 9), BTXN
(n = 5), atenolol (n = 8), TEA (n = 10) or IBTX (n = 6), respectively.
In separate series of experiment the vasomotor effect of perivascular bloodwas investigated
by adding autologous hemolysed blood (HB) directly into the vessel chamber. Hemolysed
blood (200 μL) was prepared by osmolysis from 40 μL whole blood (B) and 160 μL bidestillated
water (DW) at ratio B:DW = 1:4, as previously described [23].
At the end of each experiment the passive diameters of the vessels were measured at 80
mmHg intraluminal pressure in the presence of Ca2+-free Krebs’ buffer containing the L-type
Ca2+ channel inhibitor nifedipine (10−4 M) to achieve maximal vasodilatation. All drugs were
purchased from Sigma Aldrich (Budapest, Hungary), except ODQ, SQ22536 and iberiotoxin
(Cayman Europe, Tallinn, Estonia). Nebivolol was provided as gift by Berlin-Chemie/A.
Menarini Ltd.
Half-maximal concentrations (EC50) were calculated from nonlinear regressions of the
dose-response curves of nebivolol using SigmaPlot for Windows 11.0 software.
Assessment of vascular smooth muscle calcium ion level
As describedpreviously [23, 36, 37] changes in intracellular Ca2+-ion concentration were
assessed with ratiometric (R) calcium-measurement at the wavelength of 340 nm and 380 nm
using 5-Oxazolecarboxylic acid, 2-(6-(bis(2-((acetyloxy)methoxy)-2-oxoethyl)amino)-5-(2-(2-
(bis(2-((acetyloxy)methoxy)-2-oxoethyl)amino)-5-methylphenoxy)ethoxy)-2-benzofuranyl)-,
(acetyloxy) methyl ester (Fura2-AM; Invitrogen, Life Technologies, Budapest, Hungary) fluo-
rescent dyes [38, 39]. During the incubation period of cannulated and pressurized artery the
physiological Krebs solution was supplemented with Fura2-AM (5 μM) fluorescent Ca2+ indi-
cator dye and BSA (bovine serum albumin; 1%) for 60 min during which spontaneous myo-
genic tone developed.We have used fluorescent microscope to measure intravascular Ca2+
concentrations by an IncyteIm2 instrument (Intracellular Imaging Inc, Cincinnati, OH, USA)
by recording images (cutoff>510 nM) excited alternatively by 340 and 380 nm wavelengths.
Images were recorded every 4 s and evaluated offline. Arterial Ca2+ concentrations were
detected by calculating ratios (R) between averaged signal intensity at 340 and 380 nm excita-
tion wavelengths in the whole arterial segment. Following the protocol of Nelson’s group the
ends of the arteries were closed by pinching to prevent the Fura2 AM solution from diffusing
into the vessel lumen where it could conceivably load the endothelium [40]. In addition,
before loading the arteries with Fura2-AM, all the side-branches of the cerebral arteries have
been closed in order to prevent the accidental endothelial loading by the fluorescent dye.
data of diameter changes (normalized diameter [PD%]) of BA in response to ACh (10−4 M) and SNP (10−4 M) in
the presence of guanylate cyclase inhibitor ODQ ((Fig 1(F); n = 7). Changes in basal diameter of BA (Fig 1(H)) in
response to beta-2 adrenoceptor antagonist butoxamine (BTXN; n = 5), BKCa channel blocker iberiotoxin (IBTX;
n = 6), and KCa channel blocker tetraethyl-ammonium chloride (TEA; n = 10). Data are mean ± S.E.M.
(*significant compared to control; p<0.05).
doi:10.1371/journal.pone.0164010.g001
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Statistical analysis
Experimental results are presented as mean ± S.E.M. Data are expressed as either micrometer
or percentage of passive diameter [PD%]. The changes in ratiometric intracellular calcium
measurements are indicated as a delta ratio (ΔR). Statistical analysis was performed by one-
way ANOVA (Holm-Sidak method) or Student’s t-test as appropriate by SPSS 11.0 for Win-
dows software. P-values <0.05 were considered to be statistically significant. Figures were
made by SigmaPlot 11.0 for Windows software.
Results
Functional assessment of the endothelium removal and the vasomotor
function of endothelium and smooth muscle of isolated basilar artery
Endothelium removal reduced significantly the basal diameter from 280±30 μm to 220±29 μm
(by -16±6 [PD%]; (Fig 1(A)). The presence of functional endothelium and viability of smooth
muscle were evaluated by the administration of an endothelium-dependent dilator agent ace-
tylcholine (ACh; 10−4 M) and a smoothmuscle dependent dilator agent sodiumnitroprusside
(SNP; 10−4 M). In vessels with intact endothelium (E+), ACh elicited significant dilation
(changes in diameter;ΔD: 113±8 μm; 32±5 PD%), whereas in vessels without endothelium (E-)
the ACh-induced dilation was nearly completely eliminated (ΔD: 2±1 μm; 0.5±0.3 PD%). SNP
elicited significant dilations both in the presence and absence of the endothelium (E+ ΔD: 110
±10 μm; 32±6 PD% and E- ΔD: 83±19 μm; 26±7 PD%; Fig 1(B)). Endothelium removal was
accepted when ACh-induced dilation was diminished, while SNP-induced dilation was main-
tained indicating the viability of smoothmuscle of basilar arteries.
Effect of nebivolol on the diameter of isolated basilar artery
In the presence of 80 mmHg intraluminal pressure, the basal diameter of BA was 235±16 μm,
whereas their passive diameter was 417±12 μm. Original record in Fig 2(A) shows that nebivo-
lol (10−5 M) elicited an increase of the diameter of a basilar artery as a function of time (from
220 μm to 296 μm). Summary data (Fig 2(B)) shows that increasing concentrations of nebivolol
elicited significant dilations of BA (from 10−7 M: by -0.53±0.5 [PD%] to 10−4 M: by 35±6 [PD
%], n = 9). This finding and the EC50 range corresponds to those found by others [17, 34, 35],
namely, that the EC50 of nebivolol is 7.8 ± 0.2 x 10−6 M. Thus we performed the experiments
with specific inhibitors challenging the vasomotor effect of 10−5 M nebivolol.
Effect of inhibitors with known mechanisms of action on the nebivolol-
induced dilation of isolated basilar artery
Next, we have studied the effect of NOS inhibition on nebivolol-induced dilation of BA. We
found that L-NAME significantly reduced the basal diameter of BA (Fig 1(C); from 188±10 μm
to 162±10 μm; by -7.3±1.6 [PD%]; n = 5). The soluble guanylate cyclase blocker ODQ did not
affect the basal diameter of BA (from 226±14 μm to 225±16 μm; by -0.5±2.6 [PD%]; n = 12;
Fig 1(E). In control conditions, ACh and SNP elicited significant dilations of BA (35.3±3.1 [PD
%] and 33.6±1.3 [PD%]). In the presence of ODQ the ACh-induced dilations were not affected
significantly, while SNP-induced dilations were completely diminished of BA (31.4±4.7 [PD%]
and 2.2±1.5 [PD%]; n = 7; Fig 1(F)). The adenylyl cyclase blocker SQ22536 significantly
increased the basal diameter (from 283±9 μm to 322±7 μm; by 9±1.7 [PD%]; n = 9; Fig 1(D).
Increasing concentration of the specific beta-1 antagonist atenolol (10−6 M to 10−4 M) did not
change the basal diameter of BA (10−6 M: from 221±12 μm to 222±13 μm; 10−5 M: from 222
±13 μm to 227±13 μm; 10−4 M: from 227±12 μm to 234±13 μm, n = 10) Fig 1(G).
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Fig 2. Original record of diameter changes [μm] of a rat basilar artery in response to nebivolol 10−5 M as a
function of time (Fig 2(A)). Summary data of diameter changes (as a % of passive diameter; [PD%]) of
basilar artery (BA) in response to increased concentrations of nebivolol (10−7–10−4 M). EC50 = 7.813 ± 0.19 x
10−6 M. Data are mean ± S.E.M. (*indicate significant changes compared to control; p<0.05; n = 9 (Fig 2(B)).
doi:10.1371/journal.pone.0164010.g002
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Furthermore, the beta-2 adrenoceptor antagonist butoxamine (BTXN) did not change the
basal diameter (control 240±17 μm, BTXN: 252±25 μm, n = 5; Fig 1(H). Similarly, the KCa
channel blocker tetraethylammonium (TEA) (control: 272±14 μm, TEA: 258±23 μm, n = 10)
or the BKCa channel antagonist iberiotoxin (IBTX) (control: 248±15 μm, IBTX: 242±10 μm,
n = 6; Fig 1(H)) did not affect the basal diameter of basilar arteries, confirming the results of
previous studies [35].
Summary data (Fig 3) shows that nebivolol (10−5 M) elicited significant dilations of BA (by
23.4±3 [PD%]; p<0.05; n = 9). Nebivolol-induced dilation of BA was not affected after incuba-
tion and in presence of ODQ (by 20.5±1.5 [PD%]; p>0.05; n = 8).
The reduction of nebivolol-induced dilation increasedwith the following order: butoxamine
(by 15.5±2.1 [PD%]; p<0.05; n = 5), iberiotoxin (by 15.3±1.5 [PD%]; p<0.05; n = 6), TEA (by
15.04±2.55 [PD%]; p<0.05; n = 10), endothelium-denudation (by 13.3±3.7 [PD%]; p<0.05;
n = 10), L-NAME (by 12.8±2.6 [PD%]; p<0.05; n = 5), SQ22536 (by 11.7±3.3 [PD%]; p<0.05;
n = 9). Whereas, atenolol (by 1.4±2.2 [PD%]; p<0.05; n = 8), completely eliminated the dila-
tion to nebivolol.
Changes in [Ca2+]i of isolated basilar artery in response to nebivolol
Original images (Fig 4(A) and 4(B)) show that nebivolol elicited significant reduction (green
color indicate low and red color indicates high vascular Ca2+ levels) in ratiometric Ca2+-signal
(delta Ratio;ΔR) and elicited an increase in diameter of a basilar artery. Summary data (Fig
4(C)) shows that nebivolol decreased the ratiometric Ca2+ signal (ΔR) in a concentration-
dependent manner (10−8 M: -0.007±0.005 vs. 10−5 M: -0.113±0.031). Nebivolol elicited dila-
tions of basilar arteries with the consequent decrease in intracellular Ca2+ concentration.
Effect of nebivolol on the diameter of isolated basilar artery in the
presence of hemolysed blood
In a recent study we have found that perivascular hemolysed blood induces substantial con-
striction of isolated basilar arteries by increasing smoothmuscle [Ca2+]i [23]. Original record
in Fig 5(A) shows that adding hemolyzed blood to the perivascular area elicits substantial con-
striction of basilar arteries (BA, from 210 μm to 115 μm). Then, additional administration of
increasing concentrations of nebivolol into the vessel chamber elicited dilation in a concentra-
tion-dependentmanner (10−7 M: 125 μm; 10−6 M: 148 μm; 10−5 M: 224 μm) and in essence,
completely reversed the constrictor effect of HB. In Fig 5(B) summary data shows that the con-
strictor effect of perivascular hemolyzed blood could be reversed by adding nebivolol in the
presence of HB. HB caused significant constrictions of BA (from 219±11 μm to 148±11 μm;
-18,5±1,9 [PD%]), which was completely reversed by adding increasing concentrations (from
10−7 M to 10−5 M) of nebivolol (10−7 M: 2,3±1,6 [PD%]; 10−6 M: 5,1±1,4 [PD%]; 10−5 M: 16±3
[PD%]). Interestingly, nebivolol induced dilation at a concentration of 10−5 M reached the con-
trol basal diameter of basilar arteries (control basal diameter 219±11 μm; HB: 148±11 μm;
Nebivolol 10−5 M in the presence of HB: 209±9 μm).
Discussion
As far as we know, this is the first study to demonstrate that nebivolol elicits dilation of isolated
cerebral arteries. Nebivolol seems to have specific regional effect, because the cerebrovascular
dilation is mediated by several, parallel acting vasomotor mechanisms including endothelium-
derivedNO and cAMP linkedmechanisms, beta-1/2 adrenoceptors, hyperpolarizing factor(s)/
BKCa channels, finally, converging on the reduction of smooth muscle Ca2+ levels. In addition,
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nebivolol reversed the hemolysed blood-inducedconstriction. Thus nebivolol may be effective
in the improvement of cerebral circulation in diseased conditions.
Interestingly, on the basis of early investigations and clinical applications—for many years
—only the beta-1 receptor effect of nebivolol was considered as a potential therapeutic value.
Then, first Ignarro et al showed that nebivolol has additional effect, namely eliciting dilation
of peripheral arterial vessels, primarily, via activating the NO-pathway [3]. Previous findings
Fig 3. Summary data of diameter changes (normalized dilation; % of passive diameter; [PD%]) of BA in response to nebivolol (10−5 M) in the
presence of guanylate cyclase inhibitor ODQ, beta-2 selective adrenoceptor antagonist butoxamine (BTXN), large conductance calcium-
activated potassium channel antagonist iberiotoxin (IBTX), KCa channel antagonist tetraethyl-ammonium chloride (TEA),endothelium
denudation, NO synthase inhibitor L-NAME, adenylyl cyclase inhibitor SQ22536 and beta-1 selective adrenoceptor antagonist atenolol. Data
are mean ± S.E.M. ($ indicate significant change compared to basal diameter, p<0.05; * indicate significant changes compared to nebivolol, p<0.05; #
indicate significant change between nebivolol vs atenolol, p<0.05).
doi:10.1371/journal.pone.0164010.g003
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Fig 4. Representative pictures of Fura-2 AM fluorescence of ex vivo preparation of BA in absence (control; Fig 4(A)) and presence (Nebi;
Fig 4B)) of nebivolol (10−5 M). Green color indicates low vascular Ca2+ level and red color indicates high vascular Ca2+ level. Summary
data of changes in ratiometric signal (delta R) indicates decreasing vascular [Ca2+]i of BA in response to increasing concentrations of
nebivolol (10−8–10−5 M). Data are mean ± S.E.M. *indicate significant changes between nebivolol 10−7 M and 10−5 M; p<0.05); n = 9 (Fig 4
(C)).
doi:10.1371/journal.pone.0164010.g004
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Fig 5. Original record shows the vasomotor function of perivascular hemolyzed blood (HB) and the
vasomotor function of additional increased concentrations of nebivolol (from 10−7 M to 10−5 M) of
basilar artery. The diameter was not followed continuously in Fig 5(A). Summary data of changes in
normalized diameter (% of passive diameter; [PD%]) of basilar arteries in response to hemolyzed blood (HB)
and in response to nebivolol (from 10−7 to 10−5 M) in the presence of HB; n = 6. Data are mean ± S.E.M.
(* indicate significant difference compared to basal diameter, p<0.05; # indicate significant difference
between HB and nebivolol in the presence of HB, p<0.05); Fig 5(B).
doi:10.1371/journal.pone.0164010.g005
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[4–6, 41] initiated our study in cerebral arteries, in which the potential, additional vasomotor
effects of nebivolol could be elucidated. The results of our studies show that nebivolol dilates
cerebral arteries, an effect which is—in part—independent of beta-1 receptor mediation, sug-
gesting—at least the possibility—that in vivo it can facilitate cerebral blood flow. The findings
that dilator effect of the cerebral arteries is mediated by reduction of smoothmuscle Ca2+ also
suggest that even in the presence of endothelial dysfunction nebivolol can elicit dilation. These
assumptions, of course should be confirmed by future studies.
Vasomotor effects of Nebivolol
Nebivolol is a 3rd generation widely used beta-blocker [7–10] drug with antiarrhythmic and
antihypertensive effect [8, 42]. In addition, it has been discovered that nebivolol has vasomotor
effects, which seems to unrelated to its direct beta-1 receptor mediated action. Namely in
peripheral arteries nebivolol induces dilation [8, 11] in part, via increasing the activity of eNOS
(endothelial nitric oxide synthase) thereby upregulating NO-cGMP (cyclic-guanylate mono-
phosphate) pathway [17] resulting in vasodilation [19, 20].
It seems that the effects of nebivolol are organ/tissue specific, because in rat aortic rings
Ignarro [17] found both endothelium-dependent and -independentmediation of relaxations,
but several other mechanisms have been describedunderlying vasodilator effect of nebivolol.
For example Evangelista et al. reported that antioxidant properties of nebivolol can increase
the “surviving” level of NO by reducing its oxidative inactivation in human umbilical vein
endothelial cells, and that beta-1/2/3 adrenoceptors may play role in the development of nebi-
volol-induced dilation [43]. Moreover, Georgescu et al. showed nebivolol induces beta-2 adre-
noceptor-mediated and Ca2+ activated potassium channel induced hyperpolarizationwith the
consequent relaxation in mice renal arteries [35], whereas, Tran-Quang et al. has demonstrated
nebivolol-induced specific, either beta-2 and beta-3 agonist or alpha-1 and beta-1 antagonist
adrenoceptor-mediated relaxations in rat aortic rings [44]. It was also observed that nebivolol
elicits the release of hyperpolarizing factor via activation of calcium activated potassium chan-
nels [34] that—in part—maintains vessel relaxation when eNOS (endothelial NO synthase) is
inhibited [17]. Such parallel and backup mechanisms would be particularly important, when
NOS (NO synthase) activity, NO bioavailability, and/or other signalingmechanisms are
impaired, such as increased oxidative stress and ischemic heart diseases [45–47].
Interestingly, several studies reported that other beta-blockers also induce relaxations in
both peripheral and central arteries. Among others, Sakanashi et al. found propranolol-
induced relaxation in canine coronary arteries and raised the possibility that propranolol
reduces the calcium-influx [48]. Priviero et al showed that propranolol-induced relaxation in
rat aorta and mesenteric arterymay occur, independent of beta-adrenoceptor blockade, via
inhibition of calcium influx [49]. Similarly, Cekic et al suggested, that nonspecific beta-blocker
propranolol exhibited calcium antagonist activity in rat basilar arteries [50].
The finding of these studies lead us to hypothesize that nebivolol elicit relaxation of cerebral
arteries, an idea which has not yet been tested in a controlled experimental conditions, but can
have important clinical significance.
Nebivolol induces dilation of cerebral arteries
Interestingly, as mentioned above, there are no data available regarding the vasomotor effects
of nebivolol in cerebral vessels. Thus we aimed to characterize the dilator properties of nebivo-
lol in isolated basilar arteries, in such conditions, in which the intraluminal pressure and extra-
vascular environment were controlled. Based on previous studies [17, 34, 35, 44] we have used
nebivolol in a range of 10−7 to 10−4 M which is in accordance with a range of concentrations
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used by others. Our data show significant dilations of BA in response to concentration-depen-
dent administration of nebivolol (Fig 2). Since the EC50 is 7.8 ± 0.19 x 10−6 M, we performed
measurements with specific inhibitors near this EC50 range in the presence of nebivolol arbi-
trarily at 10−5 M. Despite the calculated pharmacologically relevant plasma concentrations in
humans after taking 5 mg nebivolol orally, it is in the nM range, but it still elicits a significant
decrease in systemic vascular resistance [44], and it may result in dilation in human cerebral
arteries. It is also possible that smaller cerebral vessels are even more sensitivity to nebivolol, as
it is a general characteristics of microvessels that their sensitivity to various drugs and stimuli
increases as the size (diameter) of vessels decreases [51].
Role of endothelium in nebivolol-induced dilation of basilar artery
The basilar artery (BA) branching of from vertebral arteries thus it has a special role in main-
taining an adequate blood flow and blood pressure, which then equilibrate in the Circle of
Willis and brainstem, as well [52].
It is well known endothelium is an important active mechanical and biological interface
between the circulating blood and surrounding tissues. It has many special function from gas
exchange to vasomotor [53] and barrier function. Vasomotor function of endothelium includes
sensing of wall shear stress associated with blood flow velocity changes and other autocrine
and paracrine signal transductionsmechanism and substances [54] [55]. Thus in many
instances, removal or impairment of endothelium has a significant influence on vasomotor
tone and function. In the present study we have confirmed previous findings that absence
of endothelium significantly decreased the basal diameter of cerebral arteries by ~ 60 μm
(Fig 1(A)) supporting a putative role for maintaining basal tone [1, 56, 57].
Role of NO in maintaining basal tone of BA
Results coming from aforementioned investigations demonstrated a special role of NO in
maintaining basal tone. As previously described [4], we have also confirmed that in basilar
arteries endogenous NO (produced by endothelium) contributes to the development of basal
vascular tone as administration of L-NAME significantly decreased (Fig 1(C)) the basal diame-
ter by ~ 30 μm, supporting previous findings [24, 52], and underlying the physiological impor-
tance of NO in the regulation of vasomotor tone of cerebral arteries [1, 56, 57].
Endothelium dependent and smooth muscle dependent vasomotor
effects of nebivolol
Importantly, nebivolol was able to induce significant, but reduced dilation of basilar artery in
absence of endothelium (Fig 3), suggesting that nebivolol may act—in part—by mediation of
vascular endothelium, but it has direct smoothmuscle effects as well. The findings of our
experiments are in accordance with those of previous studies showing that nebivolol-induced
relaxations are significantly greater in the presence of intact endothelium than in the absence
of endothelium. [12, 17–20, 35, 42].
Role of eNOS-NO and cGMP/cAMP pathways in the development of
nebivolol-induced dilation
Previous studies showed that the basal tone of peripheral arteries is modulated by NO [3, 29,
58] and that nebivolol induces an eNOS/NO-mediated dilations in peripheral arteries [17–20,
42]. In the recent study we have found that presence of eNOS blocker L-NAME significantly
decreased the basal diameter of BA in accordance with previous studies [4–6, 41] (Fig 1(C)).
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More importantly, we found that the dilations of isolated rat basilar arteries to nebivolol was
also reduced in the presence of L-NAME (Fig 3), suggesting that NO is involved in the media-
tion of the response. Most previous studies suggest that NO increases the level of the smooth
muscle soluble guanylate cyclase (sGC) enzyme producing cyclic-guanylate monophosphate
(cGMP). Then, cGMP activates protein kinase-G (PKG) [59], which is responsible for inacti-
vating the myosin light chain kinase (MLCK).MLCK would be the essential enzyme in the
development of vasoconstriction,which is inhibited by elevated level of PKG thus resulting in
dilation [60].
In addition, previous studies assigned an important role for the cyclic-adenosinemono-
phosphate (cAMP) produced by adenylyl cyclase (AC) mechanism in mediation of various
dilator responses of vessels [61]. cAMP can 1) activate protein kinase-A (PKA) thereby inacti-
vating MLCK resulting in dilation (Fig 6), 2) activate calciumATPase thus reducing [Ca2+]i
leading to vasodilation, 3) inhibit calcium-calmodulin complexes thereby inducing vasodila-
tion. Therefore we performed experiments to block synthesis of both cAMP [32] (with
SQ22536) and cGMP (with ODQ).
In contrast to previous studies (canine coronary and pulmonary arterial rings, human fore-
arm) [17–20], but similarly to Ogawa et al. [62], we have found that the sGC-inhibitor ODQ
did not decrease the basal diameter (Fig 1(E), and did not reduce the nebivolol-induced dila-
tions (Fig 3) suggesting that intracellular sGC/cGMP pathway does not contribute significantly
to the development of nebivolol-induced dilations of cerebral vessels.We explain these findings
by the presence of sGC/cGMP independent NO pathway(s) [62–69]. Indeed, there is evidence
that in certain vessels the vasodilator effect of NO are mediated via COX-dependent, cAMP
mediated pathway [62, 67–69], for example in rat retinal blood vessels [62, 63] that are ontoge-
netically are closely related to cerebral vessels. However, it has also been shown that NO can
act directly to Ca2+-dependent K+ channels in vascular smoothmuscle cells, which cause a dila-
tor response [64, 66] or by decreasing Ca sensitivity of arteriolar smooth muscle [37].
Our data shows that AC inhibitor SQ22536 exhibited significant increase in basal diameter
(Fig 1(D)) suggesting the presence of a tonic release of a constrictor factor and/or SQ22536
may elicit nonspecific enzyme inhibition [70]. Yarova et al. showed that beta-1 agonist in pres-
ence of endogenous/exogenous inductor (acetylcholine) suppresses vasodilation via increase in
endothelial cAMP level [71]. If endothelial AC is blocked it can mimic the beta-1 antagonist
induced vasodilation, supporting the findings that dilation was observed in the presence of
SQ22536. In the presence of SQ22536 nebivolol-induced dilation was significantly reduced
(Fig 3), suggesting the involvement of an AC/cAMP, rather than a sGC/cGMPmechanism in
the development of nebivolol-induced dilation of basilar arteries, which seems to be activated
by NO. These results are in agreement with findings of others [62], which showed that in cer-
tain vessels NO acts via the cAMP pathway, including COX1-PGI2/PGE2-Gs pathways [62, 63,
67–69]. Thus we propose that cerebrovascular dilator effects of nebivolol depend—in part—on
endothelial mechanisms and the eNOS/NO-AC/cAMP pathway.
Involvement of beta-adrenoceptor and BKCa channels in the
development of nebivolol-induced dilation of BA
Cekic et al. showed the specific beta-1 adrenerg antagonist atenolol did not elicit relaxation of
rat cerebral arteries, whereas the non-selective propranolol induced relaxation [50]. Tran-
Quang et al demonstrated beta-1 receptor antagonist did not affect significantly the nebivolol-
induced relaxation in rat aortic rings, suggesting beta-1 receptors do not contribute to the
development of nebivolol-induced dilation [44]. Interestingly, Yarova et al showed on rat
mesenteric arteries that endothelial beta- adrenoceptor agonists decreasedACh-induced
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dilation, whereas in the presence of beta-1 antagonist atenolol, ACh-induced dilation remained
intact [71]. These findings raise the possibility that specific beta-1 adrenoceptor antagonist—in
certain circumstances—may have the characteristics of functional agonist, via blocking endo-
thelial Gs-AC-cAMP-PKA pathway, thereby decreasing the inactivation of Ca-dependent
potassium channels, resulting in endothelial and smooth muscle hyperpolarization (through
myoepithelial gap junction), leading to vasodilation [71].
In the present study we show that beta-1 selective antagonist atenolol did not significantly
affect basal diameter of BA (Fig 1(G), which may be due to either absence of an endothelial
inductor factor [50], or it may have parallel beta-2 receptor antagonist properties, as Nuttall
reported [72]. Furthermore we found that atenolol almost completely eliminated the dilations
to nebivolol (Fig 3), which can be explained by either the presence of a beta-2 antagonist effect
of atenolol (resulting in inhibition of dilation) [72] or by occupying beta-1 adrenoceptors
Fig 6. Proposed mechanisms of action of nebivolol (NB)-induced dilation of cerebral arteries (E, endothelium; SMC,
vascular smooth muscle cell). These findings demonstrate that: 1) in isolated cerebral arteries nebivolol elicits significant
dilations, 2) which may be—in part—due to beta-2 adrenoceptor (B2-R) mediated, endothelium-dependent NO and cAMP
mechanisms resulting in either reduced [Ca2+]i, and smooth muscle hyperpolarization. 3) On the other hand, its action seems to be
mediated—in part—by beta-1 (B1-R) specific blocking ability connected with parallel induced vasodilation with endothelium
derived hyperpolarization. 4) contribution of cGMP and other ion channels seem to be less important. These findings can
contribute to a better understanding of the complex effects of this beta-1-receptor blocker on cerebral circulation and implicate
important novel therapeutic potentials to improve cerebral blood flow in diseased conditions.
doi:10.1371/journal.pone.0164010.g006
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(competitive antagonism), when nebivolol could act in presence of NO. Accordingly, one can
suggest that nebivolol-induced dilation is attributed—in part—via beta-1 adrenoceptors.
Studies of Georgescu et al. [35], suggest that beta-2 adrenoceptors may play important role
in the development of nebivolol-induced dilation in mice renal artery. This prompted us to
investigate the potential mediating role of beta-2 adrenoceptors in the vasomotor action of
nebivolol in basilar artery. Fig 3 shows that presence of beta-2 adrenoceptor antagonist butoxa-
mine (BTXN) significantly decreased the nebivolol-induced dilations of BA. Beta-2 receptors
may be expressed both on endothelial cell and on vascular smoothmuscle cell. The endothe-
lium-dependent, NOmediated pathway may be one of the major functions of beta-2 receptors.
Stimulation of beta-2 receptors (expressed on vascular smoothmuscle cells) leads to the activa-
tion of AC-cAMP-PKA pathway, which induces dilation—in part—by inactivatingMLCK and
partly by activating BKCa channels [73] and hyperpolarization (Fig 6).
Bolotina et al demonstrated the involvement of BKCa channels in NO-mediated vasodilation
[64] and Georgescu et al showed the role of BKCa channels in the development of nebivolol-
induced dilation [34]. In line with previous findings, our results showed that the BKCa channel
antagonist iberiotoxin [IBTX] and TEA significantly reduced nebivolol-induced dilation (Fig
3), suggesting an important role of BKCa and hyperpolarization,mediated by endothelial NO,
and cAMP-PKA, and via beta-1 and beta-2 receptor mediated pathways, which seem to be spe-
cific for cerebral arteries.
Nebivolol decreases [Ca2+]i in basilar arteries
Previous studies also suggested that therapeutic effects of beta-blockers could be attributed to
endothelium-independentmechanisms [48–50]. Sakanashi et al. found propranolol-induced
relaxation in canine coronary arteries and raised the possibility that propranolol reduces the
calcium-influx [48]. Priviero et al showed that propranolol-induced relaxation in rat aorta and
mesenteric arterymay occur, independent of beta-adrenoceptor blockade, via inhibition of cal-
cium influx [49]. Similarly, Cekic et al suggested, that nonspecific beta-blocker propranolol
exhibited calcium antagonist activity in rat basilar arteries [50].
Since we have found that nebivolol elicits dilation of basilar arteries, we hypothesized that
regardless of proximal pathways, nebivolol reduces the Ca2+ level in smooth muscle, which
then results in dilation. Thus we investigated parallel changes in the vascular Ca2+-signal (R)
and the diameter in isolated basilar arteries utilizing the ratiometric method used in our previ-
ous studies and others [23, 36, 38, 39]. The data of present study show that increasing concen-
trations of nebivolol caused significant decrease in vascular Ca2+-signal (R) (Fig 4), indicating
decrease in vascular [Ca2+]i concentration. The decrease in ratiometric Ca2+ signal and the
consequent dilation suggest that the signal is coming primarily from the vascular smoothmus-
cle layer. This is congruent with our functionalmeasurements of diameter changes and sug-
gests that the final signalingmechanism by which nebivolol elicits dilation of cerebral arteries
is the reduction of smooth muscle intracellular Ca2+ concentration.
Clinical implications
Searching for effective pharmaceutical treatments to improve cerebral blood flow in diseased
conditions or during aging is an ongoing effort in clinical practice. In ischemic condition, such
as transient ischemic effect [74] or stroke [ischemic [75], hemorrhagic [76] the resistance of
cerebral vessel greatly increases inhibiting the appropriate supply of brain with blood flow. Our
findings show sizeable dilations of basilar cerebral arteries to nebivolol in the absence of neural
or other tissue factors. Thus, we can speculate that nebivolol could be used in clinical settings
to improve cerebral blood flow, even in diseased conditions.
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Reversal of hemolysed blood-induced constriction of isolated BA
In recent study we have found that perivascular hemolysed blood induces substantial constric-
tion of isolated basilar arteries by increasing smoothmuscle [Ca2+]i [23]. Thereby we have
tested the dilator effect of nebivolol in the presence of perivascular hemolyzed blood adding
the chamber solution. Interestingly, we have found that hemolyzed blood (HB)-induced con-
striction of cerebral arteries could be reversed by adding increasing concentrations of nebivolol
into the vessels chamber. This finding strongly suggests that nebivolol have potential therapeu-
tic value, for example, in patients with subarachnoid hemorrhage-induced cerebrovascular
spasm.
Extrapolating these experimental findings to clinical area, may open up novel therapeutic
possibilities for this novel 3rd generation beta-1 blocker. A previous trial (BEST) using pro-
pranolol to assess its effects on cerebral function in patients with subarachnoid hemorrhage
and those suffering from acute stroke showed promising improvement in the long range, but
more early death [77]. Nebivolol has been shown to be very safe and effective beta-1-blocker
[78] and is used in much lower concentration than propranolol [70], thus one can assume that
it may have less side effects in transient ischemic attack (TIA) or in various stroke conditions.
Nebivolol seems to be an appropriate antihypertensive medication in subarachnoid hemor-
rhage patients following endovascular treatment of bleeding cerebral aneurysms [79]. Thus by
dilating cerebral arteries, nebivolol may be useful in stroke patients restoring cerebral perfusion
under lower systemic blood pressure. Future clinical studies are needed to elucidate this possi-
bility and document the beneficial effects of nebivolol on cerebral circulation in various dis-
eased conditions.
Limitation of the Study
To facilitate comparison regarding mediation of the vasomotor responses to nebivolol we have
followed the experimental protocols of Georgescu et al [34, 35]. Accordingly, we have only
used the aforementioned specific KCa channel blockers on cerebral arteries. Furthermore,
because previously we have tested both TEA and iberiotoxin [80–83] we felt that we used suit-
able experimental protocols. Although, it may be viewed as a limitation of our study, it is also
likely that combined application of inhibitors may exert unexpected and unknown effects that
would be difficult to explain or interpret. Nevertheless, in future studies one would make an
attempt to block IKCa channels (TRAM34) and SKCa channels (Apamin) individually and
simultaneously with appropriate controls.
Conclusions
This is the first study showing that nebivolol induces substantial dilation of cerebral arteries
and revealed the specific potential intracellular signalingmechanisms. The main novel findings
are that in isolated rat cerebral arteries nebivolol elicits significant dilations, which is mediated
by several parallel intracellular parallel pathways, including endothelium-derivedNO and
cAMP linkedmechanisms, beta-1/2 adrenoceptors, hyperpolarizing factor(s)/ BKCa channels,
that are all seem to converge on the reduction of [Ca2+]i, level. In addition, nebivolol reversed
the constrictor effect of hemolysed blood, which was shown earlier to increase smooth muscle
Ca2+.
These findings can contribute to a better understanding of the complex effects of this beta-
1-receptor blocker on cerebral circulation and implicate important novel therapeutic potentials
to improve cerebral blood flow in diseased conditions, such as aging and hemorrhage.
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